stockportfolio.pro
Neurocrine Biosciences, Inc. (NBIX)
Healthcare · Drug Manufacturers - Specialty & Generic · NasdaqGS
Neurocrine Biosciences, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.00M | $161.63M | $451.20M | $788.10M | $1.05B | $1.13B | $1.49B | $1.89B | $2.36B | $2.86B |
| Gross profit | — | $160.37M | $446.31M | — | $1.04B | $1.12B | $1.47B | $1.85B | $2.32B | $2.81B |
| Net income | $-141.09M | $-142.54M | $21.10M | $37.00M | $407.30M | $89.60M | $154.50M | $249.70M | $341.30M | $478.60M |
| Net margin | -940.6% | -88.2% | 4.7% | 4.7% | 38.9% | 7.9% | 10.4% | 13.2% | 14.5% | 16.7% |
Source: Neurocrine Biosciences, Inc. SEC filings (10-K). 17 years of history available in the interactive view.
Explore 17 years of Neurocrine Biosciences, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track NBIX in your portfolio →
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Neurocrine Biosciences, Inc. — frequently asked questions
What is Neurocrine Biosciences, Inc.'s revenue?
Neurocrine Biosciences, Inc. (NBIX) reported revenue of $2.86B for fiscal year 2025, up 21.4% from the prior year, according to its SEC filings.
Is Neurocrine Biosciences, Inc. profitable?
Yes. NBIX earned net income of $478.60M in fiscal 2025, a net margin of 16.7%.
What is NBIX's P/E ratio?
Neurocrine Biosciences, Inc. trades at a price-to-earnings ratio of about 25.0 based on the latest data in our nightly-refreshed cache.
How fast is Neurocrine Biosciences, Inc. growing?
NBIX's revenue grew at roughly 22.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Neurocrine Biosciences, Inc.'s official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.